Phase 1 Trial of the Safety, Pharmacokinetics, and Antiviral Activity of EDP-514 in Untreated Viremic Chronic Hepatitis B Patients

CONCLUSIONS: In treatment-naïve viremic patients, oral EDP-514 was generally safe and well-tolerated, displayed PK profile supportive of once-daily dosing, and markedly reduced HBV DNA and HBV RNA.PMID:38528825 | DOI:10.3350/cmh.2023.0535

Source: Clinical and molecular hepatology - March 26, 2024 Category: Gastroenterology Authors: Man-Fung Yuen Wan-Long Chuang Cheng-Yuan Peng Wen-Juei Jeng Wei-Wen Su Ting-Tsung Chang Chi-Yi Chen Yao-Chun Hsu Guy De La Rosa Alaa Ahmad Ed Luo Annie L Conery Source Type: research